This is an unofficial archive of PsychonautWiki as of 2025-08-11T15:14:44Z. Content on this page may be outdated, incomplete, or inaccurate. Please refer to the original page for the most up-to-date information.
DPT: Difference between revisions
>LockPicker Added legal situation in germany |
>LockPicker m revised references |
||
| Line 3: | Line 3: | ||
'''N,N-Dipropyltryptamine''' (also known as '''Dipropyltryptamine''', '''DPT''', and '''"The Light"''') is a lesser-known [[psychoactive class::psychedelic]] substance of the [[chemical class::tryptamine]] class. It is closely related to [[DMT]] and is reported to be uniquely similar in its hallucinogenic intensity, albeit with a moderately longer duration and greater unpredictability relative to DMT and other psychedelic tryptamines. | '''N,N-Dipropyltryptamine''' (also known as '''Dipropyltryptamine''', '''DPT''', and '''"The Light"''') is a lesser-known [[psychoactive class::psychedelic]] substance of the [[chemical class::tryptamine]] class. It is closely related to [[DMT]] and is reported to be uniquely similar in its hallucinogenic intensity, albeit with a moderately longer duration and greater unpredictability relative to DMT and other psychedelic tryptamines. | ||
DPT was first synthesized in 1950.<ref>Li | DPT was first synthesized in 1950.<ref>{{cite journal|last1=Li|first1=J. X.|last2=Rice|first2=K.|last3=France|first3=C. P.|year=2007|title=Behavioral effects of dipropyltryptamine in rats: evidence for 5-HT1A and 5-HT2A agonist activity|journal=Behavioural Pharmacology|issn=0955-8810|eissn=1473-5849|oclc=22170289|volume=18|issue=4|pages=283-288|doi=10.1097/FBP.0b013e3281f19ca0|pmid=17551320}}</ref> Human use was first reported in 1973, where it was researched in low doses as an adjunct to therapy for alcoholism.<ref>{{cite journal|last1=Grof|first1=S.|last2=Soskin|first2=R. A.|last3=Richards|first3=W. A.|last4=Kurland|first4=A. A.|title=DPT as an Adjunct in Psychotherapy of Alcoholics|year=1973|journal=International Pharmacopsychiatry|issn=0020-8272|oclc=1753673|doi=10.1159/000467979|pmid=4150711|volume=8|issue=1|pages=104-115}}</ref> It has also been researched in high doses to induce peak experiences for terminal cancer patients.<ref>{{cite journal|last1=Richards|first1=W. A.|last2=Rhead|first2=J. C.|last3=Dileo|first3=F. B.|last4=Yensen|first4=R.|last5=Kurland|first5=A. A.|title=The Peak Experience Variable in DPT-Assisted Psychotherapy with Cancer Patients|year=1977|volume=9|issue=1|journal=Journal of Psychedelic Drugs|pages=1-10|issn=0022-393X|oclc=7565359|doi=10.1080/02791072.1977.10472020}}</ref> It has gained some notoriety for its adoption as the primary sacrament for the "Temple of the True Inner Light" in the United States, a Christian off-shoot organization who believe in the ritual use of [[psychedelics]] and refer to them as "the true flesh of God."<ref>{{cite web|title=Temple of the True Inner Light|access-date=January 9, 2020|url=http://psychede.tripod.com/}}</ref> | ||
DPT is commonly consumed via [[insufflation]] or [[orally]]. Many report the experience of insufflation to be very congestive and painful which, with the rapidness of onset, does not give the user much time to acclimate themselves to its powerful effects. It can also be administered [[intramuscular|intramuscularly]] or via [[vaporization]] after conversion to the freebase form. Smoking the freebase is reported to be the preferred route used by the "Temple of True Inner Light".{{citation needed}} | DPT is commonly consumed via [[insufflation]] or [[orally]]. Many report the experience of insufflation to be very congestive and painful which, with the rapidness of onset, does not give the user much time to acclimate themselves to its powerful effects. It can also be administered [[intramuscular|intramuscularly]] or via [[vaporization]] after conversion to the freebase form. Smoking the freebase is reported to be the preferred route used by the "Temple of True Inner Light".{{citation needed}} | ||
| Line 17: | Line 17: | ||
{{pharmacology}} | {{pharmacology}} | ||
{{Further|Serotonergic psychedelic}} | {{Further|Serotonergic psychedelic}} | ||
DPT's [[psychedelic]] effects are believed to come from its efficacy at the [[Serotonin#The 5-HT system|5-HT<sub>2A</sub>]] and [[Serotonin#The 5-HT system|5-HT<sub>1A</sub>]] [[receptor]] as a [[Agonist#Agonists|partial agonist]].<ref> | DPT's [[psychedelic]] effects are believed to come from its efficacy at the [[Serotonin#The 5-HT system|5-HT<sub>2A</sub>]] and [[Serotonin#The 5-HT system|5-HT<sub>1A</sub>]] [[receptor]] as a [[Agonist#Agonists|partial agonist]].<ref>{{cite journal|last1=Fantegrossi|first1=W. E.|last2=Reissig|first2=C. J.|last3=Katz|first3=E. B.|last4=Yarosh|first4=H. L.|last5=Rice|first5=K. C.|last6=Winter|first6=J. C.|title=Hallucinogen-like effects of ''N'',''N''-dipropyltryptamine (DPT): Possible mediation by serotonin 5-HT<sub>1A</sub> and 5-HT<sub>2A</sub> receptors in rodents|journal=Pharmacology Biochemistry and Behavior|volume=88|issue=3|pages=358-365|doi=10.1016/j.pbb.2007.09.007|pmid=17905422|pmc=2322878|issn=0091-3057|oclc= 848182005}}</ref> | ||
The role of these interactions and how they result in the [[psychedelic]] experience remains the subject of ongoing scientific investigation. | The role of these interactions and how they result in the [[psychedelic]] experience remains the subject of ongoing scientific investigation. | ||